| Abstrakt: |
L-glutamic acid (γ) monohydroxamate (L-Glu(γ)HXM) enhances the insulinomimetic activity of vanadium ions both in vitro and in vivo. Based on this ligand as a lead compound, and in order to delineate molecular features relevant to its anti-diabetic potential, 14 related derivatives, including short peptides, were synthesized by solution as well as by solid phase methodologies. In addition, hydroxamate derivatives of (+) pantothenic acid and D-biotin were prepared. The vanadium binding, capacity of the hydroxamates synthesized was apparent, yet each had a different ligand-ions stoichiometry. The in vitro lipogenic potency of several compounds toward rat adipocytes was demonstrated. Thus, vanadium complexes of L-Gln(α)HXM, L-Glu(γ)HXM-Gly, L-Aad(δ)HXM, di-Glu-γ,γ-HXM and of (+) pantothenic acid hydroxamate exhibited 82, 79, 76, 39 and 39% of maximal insulin activity, respectively. L-Aad (δ)HXM, L-Glu(γ)HXM-Gly and (+) pantothenic acid hydroxamate-by themselves -were found to possess 24, 14 and 10% of maximal insulin activity, respectively. In vivo potency, however, of L-Gln(α)HXM vanadium complex in streptozocin-treated rat diabetic model was less apparent. [ABSTRACT FROM AUTHOR] |
Full text from SpringerLink